

BIOCON BIOLOGICS FZ LLC**BALANCE SHEET AS AT MARCH 31, 2026****(All amounts in US Dollars, except share data and unless otherwise stated)**

	<u>Notes</u>	March 31, 2026	March 31, 2025
ASSETS			
Non-current assets			
Right-of-use assets	1	37,501	1,52,286
Financial assets			
Other non-current assets	2	10,211	1,658
Total non-current assets		47,712	1,53,944
Current assets			
Financial assets			
(i) Trade receivables	3	16,06,582	14,93,511
(ii) Cash and cash equivalents	4	5,10,672	3,02,993
Other current assets	5	16,554	29,397
Total current assets		21,33,808	18,25,901
TOTAL		21,81,520	19,79,845
EQUITY AND LIABILITIES			
Equity			
Equity share capital	6	10,00,000	10,00,000
Other equity	7	2,93,719	2,06,575
Total equity		12,93,719	12,06,575
Non-current liabilities			
Financial liabilities			
Lease liability		-	75,444
Total current liabilities		-	75,444
Current liabilities			
Financial liabilities			
(i) Trade payables	8	7,43,835	4,91,208
(ii) Other financial liabilities	9	42,666	88,810
Income-tax liability (net)		-	1,764
Provisions	10	1,01,300	1,16,044
Total current liabilities		8,87,801	6,97,826
TOTAL		21,81,520	19,79,845

BIOCON BIOLOGICS FZ LLC**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026****(All amounts in US Dollars, except share data and unless otherwise stated)**

	<u>Notes</u>	Year ended March 31, 2026	Year ended March 31, 2025
Income			
Revenue from operations	11	17,29,757	24,12,938
Total revenue		17,29,757	24,12,938
Expenses			
Purchases of traded goods	12	-	-
Employee benefits expense	13	7,61,820	13,44,826
Depreciation & Amortisation Expense		58,331	80,742
Finance Cost	15	9,637	19,034
Other expenses	14	8,12,870	8,53,434
Total expenses		16,42,658	22,98,036
Profit before tax		87,099	1,14,902
Tax expense			
Current tax		(45)	1,764
Deferred Tax		-	-
Total tax expense		(45)	1,764
Profit for the year		87,144	1,13,138

BIOCON BIOLOGICS FZ LLC
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026
(All amounts in US Dollars, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
I Cash flows from operating activities		
Profit after tax	87,144	1,13,138
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Depreciation and amortisation (net)	58,331	80,742
Unrealised foreign exchange loss	12,067	1,448
Interest expense	9,637	19,034
Tax expense	(45)	1,764
Operating profit before working capital changes	1,67,134	2,16,126
Movements in working capital		
(Increase/decrease in loans and advances and other assets	(1,08,781)	31,768
Increase/(decrease) in trade payable, other liabilities	2,37,883	(4,86,880)
Cash generated/(used in) from operations	2,96,236	(2,38,986)
Direct taxes paid	(1,719)	-
Net cash flow generated/(used in) operating activities	2,94,517	(2,38,986)
II Cash flows from investing activities		
Proceeds from sale of investment in subsidiary	-	-
Net cash flow generated / (used in) investing activities	-	-
III Cash flows from financing activities		
Payment of lease liability	(74,771)	(89,076)
Net cash flow (used in) financing activities	(74,771)	(89,076)
IV Net increase/(decrease) in cash and cash equivalents (I + II + III)	2,19,746	(3,28,062)
V Effect of exchange differences on cash and cash equivalents held in foreign currency	(12,067)	(1,448)
VI Cash and cash equivalents at the beginning of the year	3,02,993	6,32,503
VII Cash and cash equivalents at the end of the period (IV + V + VI)	5,10,672	3,02,993
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	5,10,672	3,02,993
Cash on hand	-	-
	5,10,672	3,02,993
Total cash and cash equivalents [Refer note 4]	5,10,672	3,02,993

BIOCON BIOLOGICS FZ LLC**Notes to financial statements for the year ended March 31, 2026****(All amounts in US Dollars, except share data and unless otherwise stated)****1. Right of use of assets**

	Building	Total
Gross carrying amount		
At March 31, 2025	4,70,542	4,70,542
Additions	-	-
At March 31, 2026	3,55,287	4,70,542
Accumulated amortisation		
At March 31, 2025	3,18,256	3,18,256
Amortisation for the quarter	(470)	(470)
At March 31, 2026	3,17,786	3,17,786
Net carrying amount		
At March 31, 2025	1,52,286	1,52,286
At March 31, 2026	37,501	1,52,756

BIOCON BIOLOGICS FZ LLC

Notes to financial statements for the year ended March 31, 2026

(All amounts in US Dollars, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
2. Other non current assets		
Balances with statutory / government authorities	10,211	1,658
	10,211	1,658
3. Trade receivables		
Other Receivables		
Unsecured, considered good	16,06,582	14,93,511
	16,06,582	14,93,511
4. Cash and cash equivalents		
Balances with banks:		
On current accounts	5,10,672	3,02,993
	5,10,672	3,02,993
5. Other current assets		
Prepayments	16,554	29,397
	16,554	29,397
6. Share capital		
Authorised		
Issued, subscribed and fully paid-up		
Equity share capital 3,670 (March 31, 2025 : 3,670) equity shares of AED 1,000 each	10,00,000	10,00,000
	10,00,000	10,00,000
7. Other equity		
Surplus in the statement of profit and loss		
Balance as per the last financial statements	2,06,575	93,437
Profit for the period	87,144	1,13,138
Net surplus in the statement of profit and loss	2,93,719	2,06,575
Total other equity	2,93,719	2,06,575
8. Trade payables	7,43,835	4,91,208
9. Other financial liabilities		
Finance Lease Liability	42,666	88,810
10. Provisions		
Provision for employee benefits		
Gratuity	1,01,300	1,16,044
	1,01,300	1,16,044

BIOCON BIOLOGICS FZ LLC**Notes to financial statements for the year ended March 31, 2026****(All amounts in US Dollars, except share data and unless otherwise stated)**

	Year ended	Year ended
	March 31, 2026	March 31, 2025
11. Revenue from Operations		
Sale of Service		
Support service cross charge to Group Companies	17,29,757	24,12,938
	17,29,757	24,12,938
12. Purchase of traded goods	-	-
	-	-
13. Employee benefits expense		
Salaries, wages and bonus	7,47,125	12,68,162
Gratuity	26,049	1,018
Staff welfare expenses	(11,354)	75,646
	7,61,820	13,44,826
14. Other expenses		
Rates and taxes	3,626	(638)
Communication expenses	21,343	15,086
Legal and professional fees	3,05,882	5,62,732
Repair and Maintenance		
Plant and machinery	184	225
Building	5,699	1,201
Others	1,396	2,576
Travelling and conveyance	40,730	26,253
Insurance	34,947	55,514
Selling expenses		
Sales promotion expenses	3,46,827	1,49,187
Printing and stationery	1,212	278
Payment to auditors	2,922	-
Miscellaneous expenses	36,035	23,593
Foreign exchange fluctuations, net	12,067	17,427
	8,12,870	8,53,434
15. Finance cost		
Interest expenses on lease liabilities	9,637	19,034
	9,637	19,034